Do you want to read an article? Please log in or register.
Multiparametric MRI and (18)F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer
Genitourinary Cancer
Related content
Genitourinary Cancer
Head-to-head comparison of GA-68 PSMA PET/CT and multiparametric MRI findings with postoperative results in preoperative locoregional staging and localization of prostate cancer
Prostate
Dinckal M, Ergun KE, Kalemci MS, Guler E, Tokac R, Ordu S, Ogut N, Ozgul S, Sanli O, Sen S, Turna B
doi: 10.1002/pros.24799
Genitourinary Cancer
Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI-Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk-Stratification Scoring System
Prostate
Takahashi T, Nakashima M, Maruno K, Hazama T, Yamada Y, Kikkawa K, Umeoka S, Tamaki M, Ito N
doi: 10.1002/pros.24821
COMMENTED
Genitourinary CancerNuclear Medicine
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial)
★ 2
Recommended and commented by
Prof. Dr Ken Herrmann, Faculty Member
Radiology
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K
doi: 10.1148/radiol.233460
Genitourinary Cancer
Evaluating Biparametric Versus Multiparametric Magnetic Resonance Imaging for Diagnosing Clinically Significant Prostate Cancer: An International, Paired, Noninferiority, Confirmatory Observer Study
Eur Urol
Twilt JJ, Saha A, Bosma JS, van Ginneken B, Bjartell A, Padhani AR, Bonekamp D, Villeirs G, Salomon G, Giannarini G, Kalpathy-Cramer J, Barentsz J, Maier-Hein KH, Rusu M, Rouvière O, van den Bergh R, Panebianco V, Kasivisvanathan V, Obuchowski NA, Yakar D, Elschot M, Veltman J, Fütterer JJ, Huisman H, de Rooij M, PI-CAI Consortium
doi: 10.1016/j.eururo.2024.09.035
Genitourinary Cancer
Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer
Prostate Cancer Prostatic Dis
Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D
doi: 10.1038/s41391-024-00930-z
Genitourinary Cancer
Clinical Factors Associated with Suspicious (18)F-DCFPyL PSMA PET Activity in Patients Initially Managed with Radical Prostatectomy including PSA
J Urol
Li EV, Bennett R, Ho A, Wong C, Mahenthiran AK, Shankar Ramesh Kumar SK, Sun Z, Savas H, Rowe SP, Schaeffer EM, Patel HD, Ross A
doi: 10.1097/JU.0000000000004298
Genitourinary Cancer
Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study
Prostate Cancer Prostatic Dis
Stopka-Farooqui U, Stavrinides V, Simpson BS, Qureshi H, Carmona Echevierra LM, Pye H, Ahmed Z, Alawami MF, Kay JD, Olivier J, Heavey S, Patel D, Freeman A, Haider A, Moore CM, Ahmed HU, Whitaker HC
doi: 10.1038/s41391-024-00920-1
Genitourinary Cancer
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [(177)Lu]Lu-PSMA-617 in the Phase 3 VISION Trial
Eur Urol
Armstrong AJ, Sartor O, de Bono J, Chi K, Fizazi K, Krause BJ, Herrmann K, Rahbar K, Tagawa ST, Saad F, Beer TM, Wu J, Mirante O, Morris MJ
doi: 10.1016/j.eururo.2024.08.021
Genitourinary Cancer
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Lancet Oncol
Karpinski MJ, Hüsing J, Claassen K, Möller L, Kajüter H, Oesterling F, Grünwald V, Umutlu L, Kleesiek J, Telli T, Merkel-Jens A, Hüsing A, Kesch C, Herrmann K, Eiber M, Hoberück S, Meyer PT, Kind F, Rahbar K, Schäfers M, Stang A, Hadaschik BA, Fendler WP
doi: 10.1016/S1470-2045(24)00326-7